Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Neurology

• Publication date

  1999-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.52.8.1555PMID 10331678
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic accuracy of alzheimer’s disease: A neuropathological study

  2009cited by this paper
• Diagnostic accuracy of Alzheimer’s disease: A clinicopathological study

  2009cited by this paper
• High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

  1998cited by this paper
• Evaluation and use of diagnostic tests in Alzheimer's disease.

  1998cited by this paper
• Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

  1998cited by this paper
• Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study

  1998cited by this paper
• Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease'

  1998cited by this paper
• Dissociation of sensory-attentional from motor-intentional neglect

  1998cited by this paper
• Development of a Specific Diagnostic Test for Measurement of β-Amyloid (1-42) [βA4(l-42)] in CSF

  1998cited by this paper
• Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan

  1998cited by this paper
• Dietary intake and cognitive function in a group of elderly people.

  1997influential reference
• Prevalence of chronic diseases in older Italians: Comparing self-reported and clinical diagnoses

  1997influential reference
• The protective effect of the olive oil polyphenol (3,4-dihydroxyphenyl)-ethanol counteracts reactive oxygen metabolite-induced cytotoxicity in Caco-2 cells.

  1997influential reference
• Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease.

  1997cited by this paper
• Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease

  1997cited by this paper
• Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease

  1997cited by this paper
• Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men.

  1997cited by this paper
• Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

  1997cited by this paper
• Comparison of dietary assessment methods in a Southern French population: use of weighed records, estimated-diet records and a food-frequency questionnaire

  1997influential reference
• Visuospatial neglect and an ipsilesional bias during the start of performance in conventional tests of neglect

  1996cited by this paper
• Cerebrospinal protein tau is elevated in early Alzheimer's disease.

  1996cited by this paper
• Dietary antioxidants and cognitive function in a population-based sample of older persons. The Rotterdam Study.

  1996influential reference
• Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

  1995cited by this paper
• The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study.

  1995influential reference
• Biosynthesis of unsaturated fatty acids in the main cell lineages of human leukemia and lymphoma.

  1995cited by this paper
• Neuropsychological assessment, 3rd ed.

  1995influential reference
• Age-associated changes in the content and fatty acid composition of brain glycerophospholipids.

  1995influential reference
• Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

  1995cited by this paper
• Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease

  1995cited by this paper
• Relationships between macronutrient intake, handicaps, and cognitive impairments in free living elderly people

  1995influential reference
• Research advances in Alzheimer's disease and related disorders

  1995cited by this paper
• Dissociation of ophthalmokinetic and melokinetic attention in unilateral neglect.

  1995cited by this paper
• Tau protein in Alzheimer's disease.

  1995cited by this paper
• A Follow‐Up Study of Age‐Associated Memory Impairment: Neuropsychological Predictors of Dementia

  1995influential reference
• Aging-Associated Cognitive Decline

  1994cited by this paper
• Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains

  1994cited by this paper
• Future directions in the development of food-frequency questionnaires.

  1994influential reference
• Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization.

  1994influential reference
• Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay

  1993cited by this paper
• [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders].

  1993cited by this paper
• Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions.

  1993cited by this paper
• Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

  1993cited by this paper
• Vascular dementia

  1993cited by this paper
• Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.

  1993cited by this paper
• Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals.

  1992influential reference
• Preventing cognitive decline.

  1992influential reference
• Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers

  1992cited by this paper
• Dementia of the Aged: Disease or Atypical‐Accelerated Aging? Biopathological and Psychological Perspectives

  1992influential reference
• Search patterns and neglect: a case study.

  1992cited by this paper
• The Mini‐Mental State Examination: A Comprehensive Review

  1992influential reference
• Lesion analysis in neuropsychology

  1991cited by this paper
• Through a looking glass. A new technique to demonstrate directional hypokinesia in unilateral neglect.

  1991cited by this paper
• Intentional motor disorders.

  1991cited by this paper
• Perceptual and premotor factors of unilateral neglect

  1990cited by this paper
• Changes in cerebral functioning associated with normal aging.

  1989influential reference
• Selective attention in hemispatial neglect.

  1989cited by this paper
• Hemispatial neglect affected by non‐neglected stimuli

  1988cited by this paper
• Normal ageing, impaired cognitive function, and senile dementia of the Alzheimer's type: a continuum?

  1988cited by this paper
• Dietary intakes and biochemical indicators of nutritional status in an elderly, institutionalized population.

  1988influential reference
• Tabelle di composizione degli alimenti

  1987cited by this paper
• Perseveration in behavioral neurology

  1987cited by this paper
• Correlates and Consequences of Eating Dependency in Institutionalized Elderly

  1986influential reference
• Varieties of perseveration: a comparison of two taxonomies.

  1986cited by this paper
• Hypergraphia: a right hemisphere syndrome.

  1986cited by this paper
• CAMDEX: A Standardised Instrument for the Diagnosis of Mental Disorder in the Elderly with Special Reference to the Early Detection of Dementia

  1986influential reference
• Anterior-posterior interhemispheric differences in the loci of lesions producing visual hemineglect.

  1985cited by this paper
• Unilateral hemispheric injury and ipsilateral instinctive grasp reaction.

  1985cited by this paper
• Neuropsychological studies of the frontal lobes.

  1984cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Intrusions and perseverations.

  1984cited by this paper
• Effects of parietal injury on covert orienting of attention

  1984cited by this paper
• Varieties of perseveration.

  1984cited by this paper
• Association between nutritional status and cognitive functioning in a healthy elderly population.

  1983influential reference
• The meaning and use of the area under a receiver operating characteristic (ROC) curve.

  1982cited by this paper
• Measurement of functional activities in older adults in the community.

  1982influential reference
• HEMI-INATTENTION AND HEMISPHERE SPECIALIZATION

  1981cited by this paper
• Verbal perseveration in aphasia.

  1981cited by this paper
• Mechanisms underlying hemispatial neglect

  1979cited by this paper
• Hemi-neglect and hemisphere rivalry.

  1977cited by this paper
• A Measure of Primary Sociobiological Functions

  1976influential reference
• Perseveration in brain-injured adults.

  1976cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975influential reference
• A simple test of visual neglect

  1973cited by this paper
• Palinacousis: persistent or recurring auditory sensations.

  1973cited by this paper
• Attention and Effort

  1973cited by this paper
• A model for the mechanism of unilateral neglect of space.

  1970cited by this paper
• Assessment of older people: self-maintaining and instrumental activities of daily living.

  1969cited by this paper
• On perseveration in aphasics.

  1967cited by this paper
• Perseveration.

  1966cited by this paper
• TWO KINDS OF MOTOR PERSEVERATION IN MASSIVE INJURY OF THE FRONTAL LOBES.

  1965cited by this paper
• A study of visual perseveration

  1963cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960influential reference
• The parietal lobe and behavior.

  1958cited by this paper
• Brain

  1878cited by this paper

• Electrochemical Aptasensor for Non-invasive Detection of Lactoferrin: A Potential Biomarker for Alzheimer’s Disease

  2026cites this paper
• CSF total tau as a proxy of synaptic degeneration

  2025cites this paper
• Developing non-invasive molecular markers for early risk assessment of Alzheimer’s disease

  2025cites this paper
• Optimizing Alzheimer's diagnosis and precision medicine: A narrative review unlocking the potential of multiomics markers

  2025cites this paper
• Blunted pressor response to peripheral sensory afferent nerve stimulation in intracerebroventricular-streptozotocin injected rats.

  2025cites this paper
• Biomarker changes associated with fornix deep brain stimulation in Alzheimer's disease

  2025cites this paper
• Linking higher amyloid beta 1‐38 (Aβ(1‐38)) levels to reduced Alzheimer's disease progression risk

  2025cites this paper
• Biomarker-related phospho-tau217 appears in synapses around Aβ plaques prior to tau tangle in cerebral cortex of preclinical Alzheimer's disease.

  2025cites this paper
• Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer’s Disease

  2024cites this paper
• Lower Prevalence of Asymptomatic Alzheimer's Disease Among Healthy African Americans

  2024cites this paper
• Associations Between Free and Cued Selective Reminding Test and Cerebrospinal Fluid Biomarkers in Amnestic Mild Cognitive Impairment

  2024cites this paper
• Assessment of Preanalytical Cerebrospinal Fluid Handling and Storage Factors on Measurement of Aβ1-42, Aβ1-40, and pTau181 Using an Automated Chemiluminescent Platform.

  2024cites this paper
• Proteomic analysis of Alzheimer’s disease cerebrospinal fluid reveals alterations associated with APOE ε4 and atomoxetine treatment

  2024cites this paper
• Real-time detection of Tau-381 protein using liquid crystal-based sensors for Alzheimer's disease diagnosis.

  2024cites this paper
• Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease

  2024cites this paper
• Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease

  2024cites this paper
• Real‐world performance of plasma p‐tau181 in a heterogeneous memory clinic cohort

  2024cites this paper
• Functional connectivity changes in neurodegenerative biomarker-positive athletes with repeated concussions

  2024cites this paper
• Early Detection of Alzheimer’s Disease-Related Pathology Using a Multi-Disease Diagnostic Platform Employing Autoantibodies as Blood-Based Biomarkers

  2023cites this paper
• Assessing the Role of Past Depression in Patients with Mild Cognitive Impairment, with and without Biomarkers for Alzheimer’s Disease

  2023cites this paper
• Proteomic Network Analysis of Alzheimer’s Disease Cerebrospinal Fluid Reveals Alterations Associated with APOE ε4 Genotype and Atomoxetine Treatment

  2023cites this paper
• Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy

  2023cites this paper
• Default mode network failure and neurodegeneration across aging and amnestic and dysexecutive Alzheimer’s disease

  2023cites this paper
• Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinson’s and Alzheimer’s Disease

  2023cites this paper
• Integration of plasma and CSF metabolomics with CSF proteomic reveals novel associations between lipid mediators and central nervous system vascular and energy metabolism

  2023cites this paper
• Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer’s Disease

  2023cites this paper
• Deciphering the clinico-radiological heterogeneity of dysexecutive Alzheimer’s disease

  2023cites this paper
• CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease

  2023cites this paper
• How far is the goal of applying β-amyloid in cerebrospinal fluid for clinical diagnosis of Alzheimer's disease with standardization of measurements?

  2022cites this paper
• Failed Performance on the Test of Memory Malingering and Misdiagnosis in Individuals with Early-Onset Dysexecutive Alzheimer's Disease.

  2022cites this paper
• Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer’s disease: a series of clinical cases

  2022cites this paper
• Alzheimer disease’s cerebrospinal fluid biomarkers differences between immigrants and natives in a Belgian memory clinic

  2022cites this paper
• Discordance and Concordance Between Cerebrospinal and [18F]FDG-PET Biomarkers in Assessing Atypical and Early-Onset AD Dementia Cases

  2022cites this paper
• A Comparison of Operational Definitions for Mild Cognitive Impairment

  2022cites this paper
• A standardised methodology for the extraction and quantification of cell-free DNA in cerebrospinal fluid and application to evaluation of Alzheimer's disease and brain cancers.

  2022cites this paper
• Neurodegenerations are diseases of the present and the future

  2022cites this paper
• Fluorescence Resonance Energy Transfer-Based Aptasensor Made of Carbon-Based Nanomaterials for Detecting Lactoferrin at Low Concentrations

  2022cites this paper
• Higher buccal mitochondrial DNA and mitochondrial common deletion number are associated with markers of neurodegeneration and inflammation in cerebrospinal fluid

  2022cites this paper
• Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome

  2022cites this paper
• A Tale of Two Platforms

  2022influential citation
• Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer’s disease

  2022cites this paper
• Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease

  2021cites this paper
• Biomarkers for the Clinical Diagnosis of Alzheimer’s Disease: Metabolomics Analysis of Brain Tissue and Blood

  2021cites this paper
• Dapsone, More than an Effective Neuro and Cytoprotective Drug

  2021cites this paper
• New frontiers in Alzheimer's disease diagnostic: Monoamines and their derivatives in biological fluids.

  2021cites this paper
• Lactoferrin and Its Detection Methods: A Review

  2021cites this paper
• Lumbar puncture patient video increases knowledge and reduces uncertainty: An RCT

  2021influential citation
• Tumor necrosis factor superfamily molecules are increased in behavioral variant frontotemporal dementia and correlate with cortical atrophy: An exploratory investigation.

  2021cites this paper
• Proteomics Landscape of Alzheimer’s Disease

  2021cites this paper
• Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives

  2021cites this paper
• Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments

  2021cites this paper
• Cerebrospinal Fluid MicroRNA Changes in Cognitively Normal Veterans With a History of Deployment-Associated Mild Traumatic Brain Injury

  2021cites this paper
• Different patterns of gray matter atrophy in behavioral variant frontotemporal dementia with and without episodic memory impairment

  2021cites this paper
• NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression

  2021cites this paper
• Solubility of Aβ40 peptide

  2021cites this paper
• Diagnostic biomarkers in Alzheimer’s disease

  2021cites this paper
• Network-constrained technique to characterize pathology progression rate in Alzheimer’s disease

  2021cites this paper
• Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment

  2021cites this paper
• Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase and ethanolamides metabolism with Alzheimer’s disease

  2021cites this paper
• An electrochemical aptasensor for amyloid-β oligomer based on double-stranded DNA as “conductive spring”

  2020cites this paper
• Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia

  2020cites this paper
• Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation

  2020cites this paper
• Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting

  2020cites this paper
• Nannoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer's disease - A cross-validation study.

  2020cites this paper
• Serum Tau Proteins as Potential Biomarkers for the Assessment of Alzheimer’s Disease Progression

  2020cites this paper
• Diagnostic Impact of Cerebrospinal Fluid Biomarkers in Atypical Dementias in Canada

  2020cites this paper
• Cerebrospinal fluid biomarkers for cognitive disorders. An introductory overview

  2020cites this paper
• Peripheral serum metabolomic profiles inform central cognitive impairment

  2020cites this paper
• Nanomedicine against Alzheimer's and Parkinson's disease.

  2020cites this paper
• PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers

  2020cites this paper
• Safety and efficacy of Melissa officinalis extract containing rosmarinic acid in the prevention of Alzheimer’s disease progression

  2020cites this paper
• APOEɛ4-TOMM40L Haplotype Increases the Risk of Mild Cognitive Impairment Conversion to Alzheimer’s Disease

  2020cites this paper
• Blood Biomarkers of Cognitive Health and Neurodegenerative Disease

  2020cites this paper
• Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease

  2020influential citation
• Progressive dysexecutive syndrome due to Alzheimer’s disease: a description of 55 cases and comparison to other phenotypes

  2020cites this paper
• Clinical significance of fluid biomarkers in Alzheimer’s Disease

  2020cites this paper
• Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40 and 42 in human cerebrospinal fluid

  2020cites this paper
• Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis

  2020cites this paper
• Association Between Cerebrospinal Fluid Biomarkers and Age-related Brain Changes in Patients with Normal Pressure Hydrocephalus

  2020cites this paper
• Fluid Candidate Biomarkers for Alzheimer’s Disease: A Precision Medicine Approach

  2020cites this paper
• Elevated cerebrospinal fluid total tau in former professional athletes with multiple concussions

  2019cites this paper
• Locus coeruleus MRI contrast is reduced in Alzheimer's disease dementia and correlates with CSF Aβ levels

  2019cites this paper
• Amyloid cascade upstream players as new biomarker candidates in the framework of the new conceptualisation of Alzheimer’s disease

  2019cites this paper
• Plasma Levels of Soluble AβPPβ as a Biomarker for Alzheimer’s Disease with Dementia

  2019cites this paper
• Cerebrospinal Fluid and Plasma Tau as a Biomarker for Brain Tauopathy.

  2019cites this paper
• Peripheral Serum Metabolomic Profiles Inform Antecedent Central Cognitive Impairment in Older Adults

  2019cites this paper
• Biomarkers of Alzheimer's Disease

  2019cites this paper
• A New Approach for the Diagnosis of Systemic and Oral Diseases Based on Salivary Biomolecules

  2019cites this paper
• Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease

  2019cites this paper
• Tau Related Pathways as a Connecting Link between Epilepsy and Alzheimer's disease.

  2019cites this paper
• Predicting Development of Alzheimer’s Disease in Patients with Shunted Idiopathic Normal Pressure Hydrocephalus

  2019cites this paper
• Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer’s disease and associated with CSF-TAU and FDG-PET

  2019cites this paper
• Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases

  2019cites this paper
• Understanding the Contributions of Alzheimer’s Disease & Cardiovascular Risks to Cerebral Small Vessel Disease Manifest as White Matter Hyperintensities on Magnetic Resonance Imaging (MRI)

  2019influential citation
• The Use of Saliva in the Diagnosis of Oral and Systemic Diseases

  2019cites this paper
• Highly Elevated Cerebrospinal Fluid Total Tau Level Reflects Higher Likelihood of Non-Amnestic Subtype of Alzheimer’s Disease

  2019cites this paper
• Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study

  2019cites this paper
• Comparison of Mini Mental Score Examination, Quantitative Electroencephalography and Cerebrospinal Fluid Biomarkers in Clinical Practice Examining Dementia

  2019cites this paper
• Medial Temporal Atrophy in Amyloid-Negative Amnestic Type Dementia Is Associated with High Cerebral White Matter Hyperintensity

  2019cites this paper
• Increased Albumin Oxidation in Cerebrospinal Fluid and Plasma from Alzheimer’s Disease Patients

  2018cites this paper